dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
WARNINGREDOSING CAN TRIGGER PSYCHOSIS
PCP-like dissociatives can cause mania, paranoia, or psychosis that outlasts the high. High doses, redosing, and sleep loss raise the risk.
3-Me-PCPy
3-Methylrolicyclidine
M3ppy, Tolicyclidine
3-Me-PCPy is an arylcyclohexylamine derivative1 with an uncommon dual pharmacological profile, producing both dissociative and stimulant effects. Unlike most substances in its class, it combines potent NMDA antagonism with triple monoamine reuptake inhibition affecting serotonin, dopamine, and noradrenaline. It also displays high affinity for sigma receptors. This broad spectrum of activity distinguishes it from related arylcyclohexylamines, contributing to its unusual combination of stimulant and dissociative properties.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~4 mg
Light4-8 mg
Moderate8-16 mg
Strong16-25 mg
Heavy25+ mg
Duration
Onset30-60 minutes
Come Up30-120 minutes
Peak2-3 hours
Offset1-2 hours
After Effects6-24 hours
Total4-8 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Formal human studies of 3-Me-PCPy subjective effects were not located. Available descriptions come from unverified community self-reports and should not be treated as clinical evidence. Across two reports, the experience was described as combining dissociation with stimulation, euphoria, dreaminess or dazed clarity, and some motor impairment. One intranasal author also described sociability, disinhibition, mild visual movement, numbness, dizziness, and a strong urge to redose; a rectal author described restlessness, sweating, and a dreamlike dissociative state. Product identity and purity were not independently confirmed, and these individual experiences cannot establish frequency or predict effects in other people.[cite:url-nervewing-594ac1][cite:url-bluelight-383d88]
Physical
Oral or extremity numbness and some motor impairment were described in the community reports.[cite:url-nervewing-594ac1][cite:url-bluelight-383d88] Dizziness was described by the intranasal author during onset.[cite:url-nervewing-594ac1] Warm, sweaty palms were described by the rectal author.[cite:url-bluelight-383d88]
Cognitive
Dissociation was described in both unverified human self-reports, with dreamlike, dazed, or mentally clear qualities that varied by author and amount.[cite:url-nervewing-594ac1][cite:url-bluelight-383d88] Both authors described euphoria; this remains anecdotal and cannot establish a typical response.[cite:url-nervewing-594ac1][cite:url-bluelight-383d88] Both also described a stimulating or restless component alongside the dissociation.[cite:url-nervewing-594ac1][cite:url-bluelight-383d88] Increased sociability and disinhibition were reported by one experienced intranasal author and are not clinically established.[cite:url-nervewing-594ac1] That author also reported a strong urge to redose and use on multiple consecutive days; this is a single self-report, not a prevalence estimate.[cite:url-nervewing-594ac1]
Visual
Auditory
Tactile
See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives
Pharmacology
Pharmacodynamics
3-Me-PCPy acts as a potent NMDA receptor antagonist and a triple monoamine reuptake inhibitor, blocking the reuptake of serotonin, dopamine, and noradrenaline.citation needed It also functions as a high-affinity sigma receptor ligand with selectivity for the σ2 subtype.
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of 3-Me-PCPy and the metabolism of 3-Me-PCPy is unknown.
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Cross Tolerance
Dissociatives (NMDA receptor antagonists), Other arylcyclohexylamines
Harm Potential
Addiction & Dependence
Psychological
One intranasal self-report described a strong urge to redose and use on multiple consecutive days.3 This is a community harm-reduction observation rather than clinical evidence: chemical identity, purity, co-exposures, and causality were not independently verified.citation needed
Physical
No medically verified human evidence was located that can quantify physical dependence on 3-Me-PCPy. The peer-reviewed paper located for this review concerns synthesis and analytical identification rather than clinical toxicity, and absence of such reports does not establish safety.citation needed
Toxicity
Local tissue (nasal and gastrointestinal)
One intranasal self-report described intense nasal burning and next-day nosebleeds; a separate rectal self-report described localized bowel irritation after two 5 mg administrations.citation needed
Psychosis Risk
The author of that intranasal self-report warned that repeated dosing might progress toward stimulated psychosis.3 No medically verified human evidence was located that can quantify psychosis risk for 3-Me-PCPy.citation needed
Seizure Risk
Substance-specific seizure risk remains unknown; do not infer it from related arylcyclohexylamines. This is an evidence-gap statement, not a safety claim.citation needed
History & Culture
3-Me-PCPy is a synthetic arylcyclohexylamine that has emerged as a novel psychoactive substance on the research chemical market.citation needed As a structural isomer of phencyclidine, it belongs to the broader family of dissociative compounds that have been systematically explored for their…
Legality
International
The current INCB Green List exhaustively presents the substances in Schedules I-IV of the 1971 Convention and does not list 3-Me-PCPy. It lists the unsubstituted parent rolicyclidine/PCPy in Schedule I, whose chemical designation is 1-(1-phenylcyclohexyl)pyrrolidine; the convention's stated extension to stereoisomers and salts does not encompass the distinct 3-methyl derivative.
By Country
Illegal21
United StatesIllegal (analog/blanket ban)3-Me-PCPy is not named in the federal schedules, but federal law treats a qualifying analogue of a Schedule I or II substance as Schedule I to the extent it is intended for human consumption. Application depends on the statutory substantial-similarity and effect tests and is therefore fact-specific.
By state
All 50 U.S. states, the District of Columbia, and five territories were reviewed against the federal baseline. 20 jurisdictions had source-backed mirror treatment; 14 remain research gaps after independent review. 22 divergent jurisdiction findings were independently upheld.
AlabamaIllegal (analog/blanket ban)Alabama lists PCPy (rolicyclidine), 1-(1-phenylcyclohexyl)pyrrolidine, in Schedule I(d)(33). The official analytical identification of 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, also called 3-methyl rolicyclidine, shows a single phenyl-ring methyl substitution from that scheduled comparator. Schedule I(g) defines a synthetic controlled-substance analogue to include a chemically similar structure, and Schedule I(i) treats a controlled-substance analogue as Schedule I; the rule states approved-drug and qualifying investigational-use exclusions but does not condition treatment on intended human consumption. Alabama's rule is therefore broader than 21 U.S.C. § 813(a), which applies federal Schedule I treatment only to the extent an analogue is intended for human consumption; application of the state chemical-similarity standard remains fact-specific.
AlaskaIllegal (analog/blanket ban)Alaska Stat. § 11.71.150(b)(17)73
Alaska expressly places analogs of phencyclidine in Schedule IIA and identifies PCPy as the pyrrolidine example. That state schedule designation differs from the federal rule that conditionally treats a qualifying analogue as Schedule I.
ArizonaRestrictedAriz. Rev. Stat. § 13-3401(6)(d)(lvii)74
Arizona does not use the federal conditional analogue designation here. It defines phencyclidine-mimetic substances as dangerous drugs through a structural generic that expressly includes PCPY and reaches substitutions at the phenyl ring; this directly encompasses methyl-substituted PCPy without a human-consumption element.
CaliforniaIllegal (analog/blanket ban)Cal. Health & Safety Code §§ 11400-11401 (text amended by 2016 Cal. Stat. ch. 627, SB 1036)75
California treats an analog as the corresponding controlled substance for Chapter 6 penalties, but its definition is materially wider than federal law: either substantial structural similarity or substantially similar effect/representation is enough, and there is no general human-consumption element.
DelawareIllegal (analog/blanket ban)16 Del. C. § 4701(7), (10)76
Delaware includes designer drugs within 'controlled substance' for the crimes in Subchapters IV and V. Its designer-drug definition is substantially broader than the federal analogue rule because chemical similarity or merely being designed or capable of producing a similar effect suffices, without a human-consumption limitation.
FloridaIllegalFlorida directly places substituted phenylcyclohexylamines in Schedule I. The class covers a phenylcyclohexylamine with any phenyl-ring substitution and with the nitrogen included in a cyclic structure, and it expressly identifies PCPY. The Slovenian Police National Forensic Laboratory identifies 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, so its 3-methyl-substituted phenyl ring and pyrrolidine nitrogen fall within that direct class. Florida prohibits unauthorized possession and other conduct involving controlled substances without making human consumption an element of the class listing, while the settled federal analogue baseline applies only to the extent an analogue is intended for human consumption.
IllinoisIllegal (analog/blanket ban)Illinois criminalizes possession of a controlled-substance analog and treats it as the substantially similar comparator. The state definition is materially broader than federal law: it lists structural similarity, similar effect, or representation/intent as alternatives and does not require intent for human consumption.
IndianaIllegal (analog/blanket ban)Ind. Code §§ 35-48-1.1-8 and 35-48-4-0.5(b)81
Indiana defines a controlled-substance analog through structural and CNS-effect similarity and treats it as the highest scheduled comparator. Unlike the federal baseline, current Indiana treatment is not conditioned on intent for human consumption.
IowaNot scheduledIowa defines a controlled substance as a drug, substance, or immediate precursor in its five statutory schedules. Schedule I names PCPy itself as the pyrrolidine analogue of phencyclidine and extends that entry to salts and optical, positional, or geometric isomers, but it does not name 3-Me-PCPy or create a general controlled-substance-analogue category. Because 3-Me-PCPy is the 3-methyl homologue of PCPy rather than an isomer of the same molecular formula, Iowa's current schedule does not reproduce the federal conditional analogue treatment.
KansasIllegal (analog/blanket ban)Kansas prohibits possession of a controlled-substance analogue and defines an analogue intended for human consumption through alternative grounds: substantial structural similarity, substantially similar central-nervous-system effects, or a person's representation or intent concerning those effects. The state Schedule I list names PCPy, while 3-Me-PCPy is its 3-methyl homologue, so the structural-similarity ground applies without the additional effects or representation finding required by the settled federal baseline. Kansas treatment is therefore materially broader even though both regimes retain a human-consumption predicate.
MaineNot scheduledMaine's current W, X, Y, and Z schedules expressly name phencyclidine but do not name PCPy, 3-Me-PCPy, M3ppy, Tolicyclidine, or a general phencyclidine-analogue class. The schedules contain targeted derivative and generic provisions for other drug families, but no general analogue rule applicable to this 3-methyl arylcyclohexylamine. Maine therefore does not mirror the federal conditional controlled-substance-analogue treatment in its scheduled-drug provisions.
MissouriIllegal (analog/blanket ban)Missouri expressly lists PCPy in Schedule I and treats any analogue or homologue of a Schedule I controlled substance as a Schedule I substance for all state-law purposes. 3-Me-PCPy is the 3-methyl homologue of PCPy, as reflected in its verified chemical identity. Section 195.022's categorical analogue-or-homologue rule is broader than the settled federal treatment, which applies Schedule I consequences only under the federal statute's fact-specific analogue and human-consumption predicates.
MontanaIllegal (analog/blanket ban)Montana defines a dangerous-drug analogue to include material structurally related to or chemically derived from a dangerous drug in any of Schedules I through V. The state expressly lists PCPy in Schedule I and places every dangerous-drug analogue in Schedule I unless excepted or listed elsewhere, so its 3-methyl homologue is captured without the federal human-consumption predicate. This is materially stricter than the settled conditional federal analogue treatment.
NebraskaIllegal (analog/blanket ban)Nebraska treats a controlled-substance analogue intended for human consumption as Schedule I and defines the category through alternative structural-similarity or similar-effect grounds. Its Schedule I expressly lists PCPy, and 3-Me-PCPy is the corresponding 3-methyl homologue, so structural similarity alone supplies the state analogue route. Nebraska is materially broader than the settled federal baseline, which requires the federal structure-and-effect or representation criteria, although both regimes retain a human-consumption condition.
New HampshireIllegal (analog/blanket ban)New Hampshire treats a substance as a controlled drug analog when its structure is derivative of or substantially similar to a controlled drug and the statutory receptor-activity or representation-and-intent test is met. The state prohibits possession and other dealings in a qualifying analog without making intended human consumption a general element, so its coverage is broader than the conditional federal analogue baseline. Application to 3-Me-PCPy remains dependent on the statutory chemical and pharmacological facts.
New MexicoIllegal (analog/blanket ban)N.M. Stat. Ann. §§ 30-31-2(U) and 30-31-23(A), as amended by 2021 Special Session H.B. 297
New Mexico defines controlled substance analogs by substantial structural similarity or specific design for substantially similar effects and expressly identifies arylcycloalkylamines as an example class. Intentional possession of a controlled substance analog is unlawful without a separate intended-for-human-consumption element. This is broader than the conditional federal analogue treatment and encompasses a fact-specific analogue analysis for 3-Me-PCPy.
New YorkNot scheduledNew York defines a controlled substance as a substance listed in Public Health Law § 3306. The current schedule names the unsubstituted pyrrolidine analog of phencyclidine as 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy/PHP), but it does not name the distinct 3-methyl derivative and Article 33 supplies no general controlled-substance-analogue category. State scheduling therefore does not mirror the conditional federal analogue treatment of 3-Me-PCPy.
North DakotaIllegal (analog/blanket ban)N.D. Cent. Code §§ 19-03.1-01(7) and 19-03.1-23(7)100
North Dakota defines a controlled substance analog through substantial structural similarity to a Schedule I or II substance together with a similar-or-greater central-nervous-system effect or a person's representation or intent. The state separately prohibits willful possession of an analog without making intended human consumption an element of the possession offense. Its treatment can therefore be broader than the conditional federal baseline, subject to proof that 3-Me-PCPy meets the analogue definition.
Northern Mariana IslandsNot scheduled6 CMC §§ 2102(c), 2111(c), 2112, 2114, 2116, 2118, 2120, and 212210110210310410510610710810981107071
The Commonwealth defines a controlled substance as a drug, substance, or immediate precursor in its Schedules I through V, reserves additions, deletions, and rescheduling to the Legislature, and uses the nomenclature provision only to extend a listed substance across its official, common, chemical, or trade names. The current official schedules do not list 3-Me-PCPy, its systematic name 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, PCPy/rolicyclidine, or a generic arylcyclohexylamine class; Schedule III lists phencyclidine itself. Commonwealth law therefore does not reproduce the settled federal controlled-substance-analogue treatment of 3-Me-PCPy when intended for human consumption.
Puerto RicoNot scheduledPuerto Rico Controlled Substances Act, Act No. 4 of June 23, 1971, arts. 102(7), 201 and 202; Department of Health Regulation No. 153 (Regulation No. 8598), Part III, ch. I, art. 1.01111121131141151161171181191201217071
Puerto Rico defines controlled substances by its Classifications I through V, and Regulation No. 153 gives the federal schedules in 21 C.F.R. §§ 1308.11–1308.15 force of territorial law as incorporated in 2015. The incorporated Schedule I expressly names PCPy, but 3-Me-PCPy is the distinct C17H25N compound 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, whereas PCPy is C16H23N 1-(1-phenylcyclohexyl)pyrrolidine; the methylated compound is therefore not a salt or an optical, positional, or geometric isomer within PCPy's specific chemical designation. The current consolidated Act, the full Regulation No. 153, and the later declaratory orders inspected do not name 3-Me-PCPy or establish a general territorial controlled-substance-analogue rule, so territorial law does not reproduce the federal treatment of a qualifying analogue as Schedule I when intended for human consumption.
West VirginiaNot scheduledWest Virginia defines an analogue as a substantially structurally similar substance, but separately defines a controlled substance as one in Schedules I through V. Its offense provision applies to controlled substances and does not generally deem analogues controlled. Schedule I expressly lists PCPy/rolicyclidine, but not the 3-methylphenyl derivative 3-Me-PCPy.
WyomingNot scheduledWyo. Stat. §§ 35-7-1002(a)(iv), 35-7-1014(d), 35-7-1031125
Wyoming defines a controlled substance by its Schedules I through V and its operative manufacture, delivery, and possession offenses apply to controlled substances. Schedule I names the unsubstituted pyrrolidine analog of phencyclidine (PCPy/PHP), but the current Title 35 compilation does not name 3-Me-PCPy or contain a general federal-style controlled-substance-analogue treatment provision applicable to it.
ArgentinaIllegal (analog/blanket ban)Argentina controls 3-Me-PCPy through the arylcyclohexylamine chemical-group schedule in Annex II of Decree 560/2019 rather than by individual name. Its pyrrolidinyl amino ring and meta-methyl phenyl substitution match the permitted 1-pyrrolidinyl and ring-alkyl substitutions in Group 2. Article 2 treats substances within the Annex II chemical groups as estupefacientes for article 77 of the Penal Code.
AustraliaIllegal (analog/blanket ban)Criminal Code Act 1995, ss 301.1, 301.4 and 301.9; Criminal Code Regulations 2019, ss 11 and 14, Schedule 1 cl 1 item 221 and Schedule 2 cl 1 item 181678
At Commonwealth level, the current Criminal Code treats analogues of listed controlled drugs and border controlled drugs as controlled drugs. The verified identity of 3-Me-PCPy is 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, also called 3-methyl rolicyclidine. Relative to listed phencyclidine, the pyrrolidine ring and methyl substitution fall within the structural-modification routes in section 301.9(1)(c), read with the specified alkyl groups and hydrogen atoms in section 301.9(2); the catch-all in section 301.9(1)(d) also encompasses analogues, chemical derivatives and substances substantially similar in chemical structure. Phencyclidine is listed in Schedule 1 item 221 and Schedule 2 item 181 of the current Regulations, making 3-Me-PCPy a drug analogue for the Commonwealth controlled-drug and border-controlled-drug provisions.
AustriaIllegal (analog/blanket ban)Neue-Psychoaktive-Substanzen-Verordnung, Annex II, group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4910
Austria's NPS regulation covers every compound derivable from the arylcyclohexylamine, arylcyclohexyl-pyrrolidine, or arylcyclohexyl-piperidine core structures. The NPS Act penalizes commercial manufacture, import, export, transfer, or procurement when undertaken with the specified intent that the substance be used for psychoactive effect.
BelgiumIllegalRoyal Decree of 6 September 2017 regulating narcotic, psychotropic and soporific substances, Articles 2(18), 3, 6 and Annex IVB (as amended)111213
Belgium’s current consolidated Annex IVB lists Me-PCPy as 1-[1-(methylphenyl)cyclohexyl]pyrrolidine; the FDA substance record identifies 3-Me-PCPy as the 3-methylphenyl isomer of that compound. Articles 2(18) and 3 of the Royal Decree bring substances listed in Annex IV within the decree’s scope. Article 6 bars import, export, transport, manufacture, production, possession, sale, supply, delivery, and acquisition without prior authorization, which is limited to scientific or medical purposes.
CanadaIllegal (analog/blanket ban)Controlled Drugs and Substances Act, Schedule I, item 1414
Canada's Schedule I entry for phencyclidine expressly includes its derivatives and analogues and their salts. 3-Me-PCPy is the 3-methyl aryl derivative of PCPy and falls within that broad phencyclidine entry rather than appearing as a separately named substance.
ColombiaIllegal (analog/blanket ban)Colombia's sanitary code treats Ministry-designated psychopharmaceuticals, their precursors, and any other substance of analogous nature as restricted. The current national schedule names rolicyclidine (PCPy), 1-(1-phenylcyclohexyl)pyrrolidine; 3-Me-PCPy is its 3-methyl aryl analogue and is therefore covered by the statutory analogue restriction. Annex 4 separately confirms that salts and stereoisomers of nationally listed substances are also controlled.
GermanyIllegal (analog/blanket ban)3-Me-PCPy (1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine) falls within the arylcyclohexyl(methyl)amine-derived compound group in Anlage 1 no. 6 of the NpSG. Section 3 prohibits trade, placing on the market, manufacture, cross-border movement, acquisition, possession and administration except for specified recognized uses; section 4 separately criminalizes specified commercial and supply-related conduct, not possession alone.
IrelandIllegal (analog/blanket ban)Ireland's blanket-act definition covers a substance capable of producing central-nervous-system stimulation or depression with specified psychoactive changes. The Act criminalizes knowing or reckless sale, import, or export for human consumption; it does not create a general personal-possession offence.
IsraelIllegal (analog/blanket ban)Israel’s First Schedule item 11b is the PHP (PCPy/rolicyclidine) entry, and a 2017 schedule amendment expressly extends that item to its structural derivatives. 3-Me-PCPy is the 3-methyl-substituted structural derivative of PCPy and therefore falls within item 11b. It is treated as a dangerous drug under the Ordinance rather than being listed by its own name.
ItalyIllegalMinisterial Decree of 20 October 2022 amending Presidential Decree No. 309 of 9 October 199030
Italy expressly inserted 3-Me-PCPy into Table I of the national controlled-substances statute in October 2022. The decree supplies the chemical name and multiple synonyms, including 3-methylrolicyclidine and 3MEPPY.
JapanIllegalMinistry of Health, Labour and Welfare Ordinance No. 21 of 2023, amending MHLW Ordinance No. 14 of 200731323334
3-Me-PCPy and its salts are expressly listed as designated substances in Japan. The designation took effect on 20 March 2023. Under Article 76-4 of the PMD Act, manufacture, import, sale, transfer, possession, purchase, acquisition, and use outside authorized medical or other specified purposes are prohibited.
New ZealandIllegal (analog/blanket ban)New Zealand's Misuse of Drugs Act 1975 includes controlled-drug analogues in Class C when their structure is substantially similar to that of a scheduled controlled drug. PubChem records 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine and PCPy as 1-(1-phenylcyclohexyl)pyrrolidine, so the former differs from the scheduled PCPy parent only by a methyl substituent on the phenyl ring and falls within the analogue rule. It is controlled as a Class C analogue rather than through an individual 3-Me-PCPy schedule entry.
PolandIllegal (analog/blanket ban)Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 3 część 8 (Dz.U. 2024 poz. 1139, as amended through Dz.U. 2026 poz. 934)444546474849
An official EU technical-regulation document identifies 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine. Poland's current NPS schedule covers arylcyclohexylamine derivatives up to 500 u and expressly permits an alkyl substituent through C6 on the aryl ring and a pyrrolidinyl ring at nitrogen, placing this structure in group VII-NPS. Article 62b of the Act on Counteracting Drug Addiction penalizes unlawful possession of a new psychoactive substance, with higher penalties for a significant quantity. The 2025 and 2026 amending regulations do not alter group VII-NPS.
RussiaIllegal (analog/blanket ban)Government Resolution of the Russian Federation No. 681 of 30 June 1998, Schedule I entry «1-Фенилциклогексиламин и его производные, за исключением производных, включенных в качестве самостоятельных позиций в перечень», together with Note 65051525354
3-Me-PCPy is not named as an independent position, but it is covered by the express Schedule I class for 1-phenylcyclohexylamine and its derivatives. PubChem identifies 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine (C17H25N; CID 137332188) and the scheduled parent as 1-phenylcyclohexan-1-amine (C12H17N; CID 31862). Relative to that parent, the product is formed by replacing the two amine hydrogens with one divalent tetramethylene substituent, which closes the pyrrolidine ring, and replacing one phenyl hydrogen with methyl. Those substituents contain five carbon atoms in total, below the parent's twelve-carbon ceiling in Note 6. The Schedule contains no independent 3-Me-PCPy position, and no registration appears in the State Register of Medicines under the common name, English and Russian systematic names, CAS 1622348-63-3, or PubChem CID. Roszdravnadzor posts the consolidated Resolution, amended on 11 June 2025; the Schedule I heading states that circulation of its narcotic drugs is prohibited under Russian law. 3-Me-PCPy is covered as a derivative under the 1-phenylcyclohexylamine entry rather than under the bare rolicyclidine entry.
SingaporeIllegal (analog/blanket ban)The Slovenian National Forensic Laboratory identifies 3-Me-PCPy (3-methyl rolicyclidine) in an official analytical report as an NPS and confirms its systematic chemical identity. 3-Me-PCPy is not named in Singapore's current First Schedule. Singapore's Misuse of Drugs Act 1973 uses an effects-based definition covering non-excluded substances capable of stimulating or depressing the central nervous system and affecting mental functioning or emotional state; CNB states that unlisted NPS with that capacity are dealt with as psychoactive substances. Section 11I makes unauthorised possession or consumption an offence, with a defence for possession for a legitimate purpose other than human consumption.
South AfricaIllegal (analog/blanket ban)Drugs and Drug Trafficking Act 140 of 1992, Schedule 2 Part III60
Schedule 2 Part III expressly lists phencyclidine and specified congeners, including PCPy, and extends the Part to all homologues of listed substances. 3-Me-PCPy is the ring-methyl homologue of PCPy, so unauthorized use, possession, and dealing are prohibited under sections 4 and 5.
South KoreaIllegal (analog/blanket ban)마약류 관리에 관한 법률 (Narcotics Control Act), Articles 2(3)(a) and 3(5); Enforcement Decree, Article 2(3) and Annex 3 item 21616263
South Korea controls 3-Me-PCPy through Annex 3 item 21's generic phencyclidine-analogue definition. The compound's 1-pyrrolidinyl group and 3-methyl-substituted phenyl ring correspond to the definition's listed 1-pyrrolidinyl and substituted-phenyl positions. It is therefore a category-(a) psychotropic subject to the Act's general prohibition on possession, use, management, import or export, manufacture, sale, brokerage, and receipt without MFDS approval.
SwitzerlandIllegal (analog/blanket ban)Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), SR 812.121.11, Art. 1 Abs. 2, Art. 2 Abs. 2, Anhang 6, Verzeichnis e, Nr. 29164
3-Me-PCPy is covered by the generic arylcyclohexylamine entry in list e of the BetmVV-EDI. Its phenylcyclohexylamine-derived structure incorporates the amine nitrogen into a pyrrolidine ring and carries a methyl substituent on the aromatic ring, both modifications expressly encompassed by entry 291. Industrial and scientific use is exempt from control, while private use is expressly not exempt.
UkraineIllegalCabinet of Ministers Resolution No. 770 of 6 May 2000, List of Narcotic Drugs, Psychotropic Substances and Precursors65
3-Me-PCPy is the 3-methyl homologue of rolicyclidine (PCPy). Resolution No. 770 places rolicyclidine in Table I, List No. 2 and extends that list to possible homologues unless expressly excluded. Table I, List No. 2 comprises especially dangerous psychotropic substances whose circulation is prohibited.
United KingdomIllegal (analog/blanket ban)3-Me-PCPy (3-Me-rolcyclidine), chemically 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, falls within the generic arylcyclohexylamine definition in Schedule 2 Part II paragraph 1(d) of the Misuse of Drugs Act 1971. Its pyrrolidyl amino-group replacement and methyl substitution on the phenyl ring are both modifications specified by that provision. It is therefore a Class B controlled drug; unless authorized under the Act, production, supply and possession are unlawful under sections 4 and 5.
Controlled / restricted3
Czech RepublicRestrictedGovernment Regulation No. 11/2025 Coll., on the List of Listed Psychoactive Substances; Act No. 167/1998 Coll., on Addictive Substances, § 33j18192021
3-Me-PCPy is expressly named in the current annex to Government Regulation No. 11/2025 Coll. as a listed psychoactive substance, with the chemical name 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine. Section 33j of Act No. 167/1998 Coll. treats manufacture, export, import, distribution, market-directed acquisition and placing on the market as handling, and prohibits that handling except for research. The regulation also covers stereoisomers, salts and esters of listed substances where they can exist.
FinlandRestrictedFinland expressly added 3-Me-PCPy to the list of psychoactive substances prohibited from the consumer market, effective 25 September 2023. Intentional or grossly negligent manufacture, import, storage, offering for sale, or supply contrary to the Narcotics Act is punishable by a fine or up to one year of imprisonment.
MexicoRestrictedAcuerdo que modifica al diverso que establece las mercancías cuya importación y exportación está sujeta a regulación por parte de la Secretaría de Salud, Annex I(c) and (j) (DOF 01-09-2022)35363738
Mexico requires prior COFEPRIS permits to import or export raw materials or medicines that are or contain narcotics or psychotropics. Annex I lists rolicyclidine and its salts and derivatives in tariff heading 2933.99.99 for both permit regimes; PubChem identifies 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, a methyl-substituted PCPy derivative. The measure establishes a border-control restriction and does not by itself establish a general possession prohibition.
References
Source Pages
Citations
- Jason Wallach, Giorgia De Paoli, Adeboye Adejare, & Simon D. Brandt. (2014). Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. Drug Testing and Analysis, 6(7–8), 633–50. https://doi.org/10.1002/dta.14681
- Jason Wallach, & Simon D. Brandt. (2018). New Psychoactive Substances. Handbook of Experimental Pharmacology, 252, 261–303. https://doi.org/10.1007/164_2018_12412345
- Personal experience report, July 2021. nervewing.blogspot.com (n.d.). https://nervewing.blogspot.com/2021/07/3-me-pcpy.html123456789101112
- Decreto 560/2019, artículo 2 y Anexo II (Grupo 2: Arilciclohexilaminas). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-560-2019-326675/actualizacion1
- Decreto 560/2019, artículo 2 y Anexo II (Grupo 2: Arilciclohexilaminas). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/326675_dec560-2_pdf/archivo1
- Criminal Code Act 1995, ss 301.1, 301.4 and 301.9; Criminal Code Regulations 2019, ss 11 and 14, Schedule 1 cl 1 item 221 and Schedule 2 cl 1 item 181. legislation.gov.au (n.d.). https://www.legislation.gov.au/C2004A04868/2026-06-30/2026-06-30/text/original/epub/OEBPS/document_2/document_2.html1
- Criminal Code Act 1995, ss 301.1, 301.4 and 301.9; Criminal Code Regulations 2019, ss 11 and 14, Schedule 1 cl 1 item 221 and Schedule 2 cl 1 item 181. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2019L00561/2025-12-13/2025-12-13/text/original/epub/OEBPS/document_1/document_1.html1
- Misuse of Drugs Act 1973, sections 2 and 11I. policija.si (n.d.). https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/3-Me-PCPY-ID-3056-22_report.pdf1234567891011
- Neue-Psychoaktive-Substanzen-Verordnung, Annex II, group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
- Neue-Psychoaktive-Substanzen-Verordnung, Annex II, group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/eli/bgbl/i/2011/146/P4/NOR401344471
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
26 August 2026
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-Me-PCPy article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
